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Abstract
Genetic determinants of blood pressure are poorly defined. We undertook a large-scale gene-
centric analysis to identify loci and pathways associated with ambulatory systolic and diastolic
blood pressure.
We measured 24-hour ambulatory BP in 2020 individuals from 520 white European nuclear
families (the GRAPHIC Study) and genotyped their DNA using the Illumina HumanCVD
BeadChip array which contains approximately 50000 single nucleotide polymorphisms in >2000
cardiovascular candidate loci. We found a strong association between rs13306560 polymorphism
in the promoter region of MTHFR and CLCN6 and mean 24-hour diastolic blood pressure - each
minor allele copy of rs13306560 was associated with 2.6 mmHg lower mean 24-hour diastolic
blood pressure (P=1.2×10−8). rs13306560 was also associated with clinic diastolic blood pressure
in a combined analysis of 8129 subjects from the GRAPHIC Study, the CoLaus Study and the
Silesian Cardiovascular Study (P=5.4×10−6). Additional analysis of associations between variants
in Gene Ontology-defined pathways and mean 24-hour blood pressure in the GRAPHIC Study
showed that cell survival control signalling cascades could play a role in blood pressure
regulation. There was also a significant over-representation of rare variants (minor allele
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frequency <0.05) amongst polymorphisms showing at least nominal association with mean 24-
hour blood pressure indicating that a considerable proportion of its heritability may be explained
by uncommon alleles.
Through a large scale gene-centric analysis of ambulatory blood pressure, we identified an
association of a novel variant at the MTHFR/CLNC6 locus with diastolic blood pressure and
provided new insights into the genetic architecture of blood pressure.
Keywords
gene; genetics; blood pressure; single nucleotide polymorphism; association; heritability
Introduction
Raised blood pressure (BP) is the single most important risk factor for cardiovascular
diseases worldwide (1). BP is a complex trait with significant heritability (2-4). However, a
majority of the causative genes and related molecular mechanisms remains largely
unknown. Recent candidate gene studies and the first genome-wide association scans
(GWAS) have revealed that at least a fraction of BP-associated genes map to functionally
and/or clinically important signalling cascades of cardiovascular regulation (5-9). This
indicates that BP gene discovery may be greatly facilitated by large-scale systematic
analysis of variants in pathways of cardiovascular regulation. The recently developed
Illumina HumanCVD BeadChip, herewith called the 50K IBC array, permits simultaneous
genotyping of approximately 50000 common and low frequency single nucleotide
polymorphisms (SNPs) in >2000 candidate genes/loci with the highest functional relevance
to cardiovascular system (10). The overall genetic coverage for many genes related to
cardiovascular disease is denser on this array than on traditional genotyping platforms used
in GWAS. Such a selection of genetic variants enables investigations of major
cardiovascular pathways at an unprecedented scale without compromising the depth of
coverage and allows important questions about the genetic architecture of BP to be
examined.
Here we report the results of the first large-scale experiment using the new 50K IBC array in
relation to mean 24-hour systolic and diastolic BP (SBP and DBP) in a cohort of subjects
whose clinic BP values and the prevalence of hypertension are representative of the British
general population (2,5,11).
Methods
Studies, subjects and phenotypes
The major stages of our research strategy are presented in Figure 1. The primary analysis
using the 50K IBC array was performed in subjects recruited as part of the Genetic
Regulation of Arterial Pressure of Humans in the Community (GRAPHIC) Study.
Validation of the main findings from the GRAPHIC Study was carried out in subjects from
two additional European Caucasian cohorts, the CoLaus Study and the Silesian
Cardiovascular Study.
GRAPHIC Study—Details of recruitment and phenotyping of the GRAPHIC subjects are
described elsewhere (5). Briefly, nuclear families (all of white European ancestry) with both
parents (aged 40-60 years) and two adult (aged ≥18 years) offspring were identified through
general practices in Leicestershire, UK (5). Participants had a detailed history taken and
were examined by research nurses following standard protocol. Three clinic BP readings
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were made using an Omron HEM-705CP digital BP monitor. Clinic BP was defined as the
mean of the second and third readings. Ambulatory BP was measured using a Spacelabs
90207 monitor (Spacelabs, Wokingham, UK) for 26 hours. The first two hours of each
record was discarded to avoid an alerting response (5). Readings were taken at 30 minute
intervals between 8 am and 10pm and hourly between 10pm and 8am. The ambulatory BP
data were summarised weighing each time period proportional to its length (2). 2037
subjects from 520 families underwent successful ambulatory BP monitoring and were
genotyped in this project. Because of low overall genotyping call rate (<90%) or incomplete
phenotypic information, 17 individuals were excluded from the current association analysis.
CoLaus Study and Silesian Cardiovascular Study (SCS)—The recruitment
strategy and phenotyping of these cohorts have been described elsewhere (12-13) and
further details are given in online Data Supplement (please see http://hyper.ahajournals.org).
Full genetic and phenotypic information was available for 5356 and 753 biologically
unrelated subjects from CoLaus and SCS, respectively.
The studies were conducted according to the principles expressed in the Declaration of
Helsinki, approved by their respective local bioethical committees and all subjects gave
informed written consents for participation.
Genotyping and quality control filters
Genotyping platform—Detailed description of the strategy for the selection of genes on
the Illumina HumanCVD BeadChip are provided elsewhere (10). A list of the loci on the
array is available at http://bmic.upenn.edu/cvdsnp/. Further description of tagging of loci is
provided in Online Data Supplement (http://hyper.ahajournals.org).
Primary genetic association analysis—200 ng of leukocyte DNA from each subject
in GRAPHIC Study was hybridised to 50K IBC arrays (version 2) on an Illumina Bead
Station 500 (Illumina, Inc.), using protocols specified by the manufacturer. Alleles were
called using the Illumina BeadStudio (v3) Genotyping Module (based on GenCall Software
algorithms for clustering, calling and scoring genotypes). The quality of cluster plots was
visually inspected by 2 independent investigators.
DNA analysis in the CoLaus cohort and the SCS—Genotypes of SNPs showing
significant and suggestive associations with mean 24-hour BP in GRAPHIC Study (n=17)
were extracted in silico from GWAS conducted in the CoLaus cohort using the Affymetrix
Genome-Wide Human SNP Array 5.0. Of these 5 SNPs were directly genotyped by the
Affymetrix array and 10 were imputed. Information on 2 SNPs (rs4648310 and rs17037388)
was not available. The SNP that showed consistent association with BP in GRAPHIC and
CoLaus (rs13306560) was genotyped in the SCS using commercially available TaqMan
assays on ABI PRISM 7900HT Sequence Detection System (Applied Biosystems).
Statistical analysis
Heritability of BP was estimated using an algorithm implemented in Sequential Oligogenic
Linkage Analysis Routines (SOLAR v2.0) software (14). The χ2 test was used in the
parental generation of the GRAPHIC Study to examine whether distributions of genotypes
for each SNP on the 50K IBC array were concordant with Hardy-Weinberg equilibrium.
SNPs which passed this and additional filters (see Online Data Supplement
http://hyper.ahajournals.org) were examined for their associations with BP under an additive
model of inheritance using generalized estimating equations (GEE) with exchangeable
correlation structure to account for familial correlations and with adjustment for age, age2
and sex. Association analysis of top SNPs in the GRAPHIC Study with clinic BP in the
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CoLaus and SCS cohorts was based on age, age2 and sex adjusted linear regression models
fitted in PLINK http://pngu.mgh.harvard.edu/purcell/plink/ (15) under additive model of
inheritance. BP values of subjects on antihypertensive treatment in all cohorts were adjusted
for BP-lowering effect of therapy using a semi-parametric algorithm in GRAPHIC and SCS
(16-17) or adding a constant of 15 mmHg (to SBP) and 10 mmHg (to DBP) in CoLaus (9).
Genetic effects are shown as β-coefficients (β) per each extra minor allele copy of a SNP
with the respective standard error (SE).
Two sensitivity analyses [(i) no treatment correction, (ii) exclusion of subjects on
antihypertensive treatment] were undertaken to examine if antihypertensive therapy had any
impact on the observed associations.
To correct for multiple testing in the GRAPHIC Study for each association with the two
principal phenotypes (mean 24-hour SBP and DBP) we calculated false positive discovery
rate (q-values) based on the method proposed by Storey and Tibshirani (18) and available in
the QVALUE software (http://genomine.org/qvalue/). The q-value thresholds of 0.05 and
0.25 were selected to identify the findings that represent significant and suggestive
associations, respectively.
Fixed-effect meta-analysis of association between rs13306560 and clinic BP in the
GRAPHIC, CoLaus and SCS studies was conducted under additive model of inheritance
using inverse variance weighted averages of β-coefficients and SE in METAL
(http://www.sph.umich.edu/csg/abecasis/metal/index.html). The between-study
heterogeneity was evaluated using χ2 test.
Two-tail Fisher’s exact test was used to analyse the distributions of rare, exonic and non-
synonymous variants across different strata of associations with mean 24-hour mean SBP
and DBP in the GRAPHIC Study.
The power estimates of the GRAPHIC Study to detect both nominal (P<0.05) and
Bonferroni adjusted (33577 tests) effects of various sizes for mean 24-hour SBP and DBP
across a range of different minor allele frequencies were derived using the average SE
observed at each allele frequency and constructed in STATA.
An extended description of the statistical analysis is available in Online Data Supplement
(http://hyper.ahajournals.org).
Bioinformatic analysis
All SNPs on the 50K IBC array were annotated to specific loci using resources available in
public domain including information on design of the array at
http://bmic.upenn.edu/cvdsnp/, NCBI (Built 36.3) and SNP Function Portal - web-based
application for analysis of human genetic variants (19). To examine in more detail
associations between mean 24-hour BP and genes previously linked to SBP and DBP we
identified such genes using the Gene Ontology Annotation Database (GOA)
(http://www.ebi.ac.uk/GOA/downloads.html). The details of this GOA-based strategy are
shown in Table S1. Identification of processes associated with mean 24-hour SBP and DBP
was conducted using Gene set-based analysis of polymorphisms (GeSBAP) web interface
(20). Gene ontology (GO) database was used as a reference repository of functionally
annotated biological processes.
An extended description of the bioinformatic analysis is provided in Online Data
Supplement (http://hyper.ahajournals.org).
Tomaszewski et al. Page 4
Hypertension. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Results
Subjects
The characteristics of the GRAPHIC subjects included in the analysis are shown in Table 1.
The relevant characteristics of the CoLaus and SCS cohorts are listed in Table S2.
Heritability of mean 24-hour and clinic BP in the GRAPHIC Study
The narrow sense heritability (h2) of mean 24-hour SBP was marginally higher than that of
clinic SBP (h2=0.33, SE=0.05, p=8.4×10−14 vs. h2=0.31, SE=0.04, p=1.2×10−13,
respectively). The mean 24-hour DBP showed more significant heritability than clinic DBP
(h2=0.41, SE=0.05, p=3.7×10−20 vs. h2=0.32, SE=0.04, p=3.3×10−15, respectively).
Associations between SNPs on the 50K IBC array and mean 24-hour SBP and DBP in the
GRAPHIC cohort
Of 49094 genotyped SNPs, 15517 SNPs were excluded from analysis for reasons given in
Online Data Supplement (http://hyper.ahajournals.org). Of 33577 SNPs that passed all
quality filters and were included in further analysis, 32939 were annotated to 3036 loci. The
remainder (n=638) were mapped to hypothetical genes.
The distributions of nominal P-values for the associations of mean 24-hour SBP and DBP
are shown in Figure S1. The power to detect associations with each principal phenotype is
shown in Figure S2. The genomic control (λ) coefficients computed for mean 24-hour SBP
and DBP showed no inflation of the association statistic driven by stratification (λ=0.972
and λ=0.973, respectively). 1782 and 1842 SNPs that passed quality filters showed at least
nominal (p<0.05) association with mean 24-hour SBP and DBP, respectively. These
nominal associations mapped to 738 (mean 24-hour SBP) and 762 (mean 24-hour DBP)
loci.
After calculation of false positive discovery rate, only one SNP (rs2797221) in the Usher
syndrome type IIa protein gene (USH2A) showed a significant association with mean 24-
hour SBP - each extra minor allele copy of rs2797221 was associated with 3.9 mmHg lower
adjusted mean 24-hour SBP (p=8.6×10−7, q=0.0285; Table 2). Four other SNPs (rs9892909
in SPHK1, rs2283210 in KCNQ1, rs2623410 in PDE1A and rs443095 in THBS4) showed
suggestive associations with mean 24-hour SBP (Table S3). The associations of these 5
SNPs with mean 24-hour DBP are presented in Table 2 and Table S4.
Only one SNP [rs13306560 in the region between 5,10-methylenetetrahydrofolate reductase
(NADPH) gene (MTHFR) and chloride channel 6 gene (CLCN6)] showed a significant
association with mean 24-hour DBP after calculation of false positive discovery rate - each
minor allele copy of rs13306560 was associated with 2.6 mmHg lower mean 24-hour DBP
(p=1.2×10−8, q=0.0008, Table 2). Four additional MTHFR SNPs (rs17037388, rs17037390,
rs17367504 and rs13306561) as well as 8 other polymorphisms (rs4648310 in PTGS2,
rs11801879 in NPPB, rs925596 in NLRP1, rs6993502 in CPA6, rs2280232 in STAT1,
rs1035798 in AGER, rs873985 in CISH, rs12603626 in NOG) were associated with mean
24-hour DBP at a suggestive level of statistical significance after calculation of false
positive discovery rate (Table S5). The associations of these 13 SNPs with mean 24-hour
SBP are presented in Table 2 and Table S4.
In sensitivity analyses, the significant and suggestive SNPs retained their associations with
mean 24-hour SBP and DBP even without using antihypertensive treatment correction or
after exclusion of subjects on antihypertensive treatment (Tables S6-S7).
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Evaluation of significant and suggestive association signals identified in analysis of mean
24-hour BP using clinic BP in the GRAPHIC Study, CoLaus cohort and Silesian
Cardiovascular Study
The majority of SNPs showing significant or suggestive associations with mean 24-hour
SBP (n=5) and DBP (n=13) were also associated (in most instances at a lower level of
significance) with clinic BP in the GRAPHIC Study (Table 3 and Table S4). However, only
one of the associations identified in analysis of mean 24-hour BP in the GRAPHIC Study
was confirmed in relation to clinic BP in the CoLaus cohort (rs13306560 and clinic DBP;
p=0.0322, r2hat imputation coefficient – 0.88, Table 3). The other SNPs were not associated
with clinic BP in the CoLaus Study (Table S8). Further analysis based on direct genotyping
of rs13306560 in Silesian Cardiovascular Study confirmed the association of rs13306560
with clinic DBP (p=0.0094; Table 3). The direction of allelic association of rs13306560 and
clinic DBP was consistent across all examined populations. In inverse variance weighted
fixed effects meta-analysis of the three studies each minor allele copy of rs13306560 was
associated with an approximately 1.9 mmHg lower clinic DBP (P=5.4×10−6) (Table 3).
rs13306560 and 24-hour BP in the GRAPHIC Study – additional analyses
Body mass index did not have an effect on the association of rs13306560 with mean 24-hour
DBP (Table S9). We also examined the association of rs13306560 with mean daytime
(10.00-22.00) and nocturnal (00.00-6.00) DBP in the GRAPHIC Study. The SNP was
associated with DBP at both time-periods; the association with nocturnal DBP was stronger
than that of daytime DBP (daytime: β=−2.30, SE=0.56, P=3.4×10−5 and night-time: β=
−3.37, SE=0.51, P=2.9×10−11).
MTHFR/CLCN6/NPPB locus – linkage disequilibrium and functional analysis in silico
rs13306560 maps to the promoter region of MTHFR and CLCN6
(http://genome.ucsc.edu/cgi-bin/hgTracks). Four other MTHFR SNPs (rs17037388,
rs17037390, rs17367504, rs13306561) were also associated with mean 24-hour DBP at
q<0.25 (Table S5). One of these SNPs, rs17367504, was identified as the lead association
signal at this locus in a recent GWAS meta-analysis of clinic BP (9). These four additional
SNPs are in strong LD [as measured by r2 (r2>0.8)] with each other (Figure 2). However,
they are only in a very weak LD with rs13306560 (r2=0.27-0.28). rs13306560 is also in
weak LD (r2=0.3 in the GRAPHIC Study) with rs11801879 - natriuretic peptide precursor B
(NPPB) polymorphism showing suggestive association with mean 24-hour DBP in our
discovery cohort (Figure 2 and Table S5). Genetic variation within this locus was previously
associated with BP in subjects of European ancestry (7). However, our conditional analysis
(see Online Data Supplement http://hyper.ahajournals.org) indicated that the association
signal at rs17367504 and rs11801879 were both driven by their linkage disequilibrium (LD)
with rs13306560. HapMap-based LD examination in Utah residents with ancestry from
northern and western Europe (CEU population) revealed only one polymorphism
(rs13306567) as a statistically similar proxy of rs13306560 (r2=0.83) within its adjacent 500
KB (Figure S3). The proxy maps to intron 3 of MTHFR (5178 bps from rs13306560) and is
not present on the 50K IBC array. All the other SNPs within the 500 KB distance of
rs13306560 exhibit very weak LD with it (all r2<0.4) (Figure S3). rs13306560 is the only
confirmed polymorphism within the intergenic junction of MTHFR and CLCN6 (Figure
S4). This short segment shows a high GC content (64.4%) and is a part of the larger 1104-bp
CpG island spanning the 5′ flanking regions of both genes (Figure S4). The region lies
within 6 quantitative trait loci (QTLs) for BP identified in rats and 1 QTL for atherosclerosis
in mouse (Figure S4). It exhibits significant conservation across placental mammals and
scores high in evolutionary and sequence pattern extraction through reduced representations
(ESPERR) programme (that discriminates enhancer elements from neutral DNA sites with
>90% accuracy) (21). rs13306560 lies in the centre of the most conserved part of this region
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– its ancestral allele is conserved not only in primates and other mammals but also in higher
vertebrates (opossum) .
Associations between mean 24-hour SBP and DBP and BP-relevant candidate genes
To specifically investigate genes on the 50K IBC array with direct relevance to BP, we first
identified gene ontology (GO) categories that include “blood pressure” terms using the GOA
database (Table S1). This revealed 113 GO processes with 129 genes, of which 110 were
present on the array. 105 of these genes were well-tagged (Tier 1 or 2) (Tables S10-S11). In
total, 1982 SNPs were typed in these genes. Of 105 sufficiently tagged genes, only 3 (2.9%)
(NPPB, KCNQ1 and PTGS2) had SNPs within the stratum of suggestive associations
(q<0.25) with mean 24-hour SBP or DBP. Of the remaining 102 genes only one (NPPA) had
SNPs associated with mean 24-hour BP below the threshold of significance above which
associations could be attributed to pure chance only (q≥0.5) (Tables S10-S11).
We also examined the coverage on the 50K IBC array for 17 SNPs recently implicated in
BP regulation through large scale meta-analyses of GWAS (8,9). Apart from the MTHFR
variant discussed earlier, only 4 other SNPs were directly represented or had good proxies
on the array. Of these, 2 SNPs (rs3184504 in SH2B3 locus and rs17696736 in the C12orf30
locus; both on chromosome 12) showed evidence of association. Both the direction of allelic
association and effect size estimates of these 2 SNPs were consistent with the data from the
meta-analyses of GWAS (Table S12).
Pathwayomic analysis of mean 24-hour SBP and DBP
GeSBAP analysis identified 5 biological processes as significantly associated with mean 24-
hour BP after correction for multiple testing (Table S13). Of these, 2 processes (protein
kinase cascade - GO:0007243 and regulation of cell proliferation - GO:0042127) were
implicated in the regulation of both mean 24-hour SBP and DBP (Table S13).
Rare, exonic and non-synonymous variants and mean 24-hour SBP and DBP
There were no significant differences in distribution of exonic or non-synonymous variants
among SNPs showing at least nominal (p<0.05) associations with mean 24-hour BP and
those represented overall on the genotyping platform (Table 4). On the other hand, rare
SNPs (those with MAF<0.05) were over-represented within the stratum of variants
nominally associated with both mean 24-hour SBP and DBP (P=8.7×10−5 and P=0.0036,
respectively) (Table 4). This difference became even more striking when applying a lower
threshold for definition of uncommon polymorphisms (MAF<0.02); SNPs with MAF below
this cut-off were almost twice more common amongst variants associated with mean 24-
hour BP than expected by chance (P=3.0×10−6 and P=2.4×10−7 for mean 24-hour SBP and
DBP, respectively) (Table 4). However, neither exonic nor exclusively non-synonymous
SNPs were over-represented within the stratum of significant rare variants (Table 4),
irrespective of the criterion of rare variant definition. Sensitivity analysis conducted using a
lower level of statistical significance (p<0.01) confirmed these findings (Table S14).
Discussion
Our study has uncovered novel alleles, genes and pathways of BP regulation whilst showing
that a majority of the previously examined candidates are not (or only weakly) associated
with mean 24-hour BP. Mean 24-hour BP probably does not provide distinct information
compared with clinic SBP and DBP. However, it shows higher reproducibility, closer
correlations with indices of target organ damage and better predictive value of
cardiovascular morbidity (22,23). The higher heritability of mean 24-hour BP than that of
clinic measurements demonstrated particularly well for DBP in the GRAPHIC families
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suggests that 24-hour ambulatory BP monitoring (ABPM) may be particularly informative
in gene discovery. However, because of unavailability of replication resource with 24-hour
ABPM we validated our primary association findings by using clinic BP measurements in
other independent cohorts.
Our findings need to be interpreted in the context of the power of our study. At a nominal
level of significance, given the greater precision of our BP phenotypes and the population
size, our study had a good power to detect effect sizes of as low as 1 mmHg for variants
with MAF>10% (Figure S2). With Bonferroni correction, the power was significantly
diminished because of the large number of SNPs analyzed (Figure S2). However,
Bonferroni adjustment is probably over-conservative in context of SNPs on this array, given
their significant LD-driven correlations and non-independence. Nonetheless, our top signal
(rs13306560) from analysis of mean 24-hour DBP survived correction for multiple testing
based on q-value calculations. The identified association would retain its statistical
significance even after application of more conservative thresholds based on Bonferroni
correction (1.5×10−6) or those used in previous GWAS (5×10−8). rs13306560 also gave
consistent associations in relation to clinic BP in >8000 subjects from 3 European
populations making it unlikely that it represents a false positive finding.
Indeed, our conditional analysis indicates that the association with rs13306560 may largely
explain the association between BP and other SNPs at the MTHFR/CLCN6/NPPB locus
reported in recent GWAS (8-9). Quantitatively, the magnitude of rs13306560 effect on BP is
one of the largest genetic effects that have been reported to date for a relatively common
variant. Furthermore, rs13306560 shows a significant functional potential itself in silico.
Indeed, the alleles of rs13306560 are conserved in mammals and the SNP maps to CpG
island in the MTHFR/CLCN6 promoter with evidence of operation of selective pressure (to
maintain the sequence in this DNA fragment) throughout mammalian evolution. One
possible mechanism by which rs13306560 could therefore mediate the association with BP
is through differential methylation of the MTHFR/CLCN6 promoter in the two alleles.
MTHFR has a strong biological potential to influence BP regulation. It encodes an enzyme
that catalyses conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a
co-substrate for homocysteine remethylation to methionine (24). Circulating concentrations
of homocysteine have been associated with risk of cardiovascular diseases including
hypertension, possibly through promotion of free radical-mediated endothelial damage and
dysfunction (25). One of the common non-synonymous MTHFR polymorphisms
(rs1801133, −C677T or A222V) known to produce a thermolabile enzyme isoform with
reduced activity in TT homozygotes (25) was over-represented in patients with hypertension
(26). However, rs1801133 is not in LD with rs13306560 (r2=0.02) and showed only nominal
association with mean 24-hour DBP in the GRAPHIC study. rs1801133 was also only
weakly associated with clinic DBP in the recent GWAS meta-analysis of BP (9). Thus, it is
unlikely that rs13306560 mediates its effect on BP through the thermolabile form of
MTHFR.
CLCN6 belongs to a family of molecules that function as either transmembrane ion channels
or electrogenic Cl−/H+ exchangers (27). CLCN6 protein is mainly expressed in the central
and peripheral nervous system where it resides within vesicular endosomes (27).
Experimental disruption of CLCN6 leads to a lysosomal storage disease; CLCN6 knockout
mice show reduced pain sensitivity and mild behavioral abnormalities (27). CLCN6 mRNA
expression was confirmed in the kidney but whether, like other members of the chloride
transporters family (CLCNKB, CLCN5), it may contribute to renal ion handling is not
known. Importantly, mutations in several chloride channels genes underlie monogenic forms
of low blood pressure (CLCNKB) (5) and defects in tubular ion reabsorption leading to
chronic kidney disease (CLCN5) (28). While the location of rs13306560 in the promoter of
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both MTHFR and CLNC6 makes them strong candidates, recent studies have shown that
polymorphisms can act by influencing more distally located genes (29). Therefore, at this
stage we cannot exclude MTHFR, CLCN6 or in fact other genes in this locus (i.e. NPPA and
NPPB) as the mediator(s) of the identified association (Figure 2).
A notable finding in our study is that very few variants of the most frequently examined
candidates for BP (such as genes of the renin-angiotensin and sympathetic nervous systems)
which were present on 50K IBC array showed associations with mean 24-hour BP. These
data are consistent with recent GWAS which also did not report any definite associations
with such genes (9). The very good genetic coverage (exceeding that of the GWAS
platforms) for a majority of these strong candidate genes makes it unlikely that any of their
common variants (although not genotyped directly) were not captured in this analysis. This
makes our investigation one of the most comprehensive and detailed studies of these
systems for their genetic impact on BP. Collectively, these results clearly suggest that
common genetic variants underlying familial predisposition to hypertension may reside
outside classical systems of BP regulation (30). In respect to this, our pathwayomic analysis
has uncovered that signalling cascades that control cell survival through promotion of
cellular growth (i.e. mitogens activated through protein kinase cascades) and death (via
apoptosis) may play a role in BP regulation. Future systematic analyses of these pathways
may identify novel genetic determinants of human hypertension and illuminate novel
molecular mechanisms of BP regulation.
Our data also show a consistent over-representation of rare alleles amongst the SNPs
associated with mean 24-hour BP. Indeed, irrespective of the threshold of rare variant
definition, stratum of statistical significance and the phenotype, rare SNPs were associated
with BP more frequently than expected by chance. Most strikingly, rare SNPs (MAF<0.05)
constitute also the majority of significant and suggestive associations with mean 24-hour
SBP (Table 2 and Table S3). Interestingly, these over-represented rare variants do not lead
to amino acid substitutions within the encoded proteins and map to extra-exonic regions.
These results lend support to the hypothesis that rare alleles play a role in genetic
predisposition to blood pressure elevation(31) and indicate that more subtle mechanisms
than those leading to changes in amino acid structure of encoded proteins may underlie
human hypertension.
Perspectives
This large scale gene-centric analysis identified a novel association between a potentially
functional variant at the MTHFR/CLNC6/NPPB locus and BP. We also show that both
rare variants and genes that reside outside the classical physiological pathways of BP
regulation may be important elements of the genetic architecture of BP. Future studies
should focus on replication of these findings in larger cohorts and elucidation of the
functional mechanisms that underlie the uncovered associations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Major stages of the research strategy.
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Figure 2. MTHFR/CLCN6/NPPB locus - association with mean 24-hour DBP in the GRAPHIC
Study
Associations of individual SNPs with mean 24-hour DBP in the GRAPHIC Study are
plotted as −log10P against chromosomal base pair position. rs13306560 is shown as a red
diamond and its LD relationship with the other markers (including rs17367504 and
rs11801879) is indicated by colour shading (whereby: red - r2>0.8, white - r2<0.2). The
locations of known genes in the region are shown in green and the recombination hotspots
are represented as blue peaks. MTHFR - 5,10-methylenetetrahydrofolate reductase
(NADPH) gene, CLCN6 – chloride channel 6 gene, NPPB - natriuretic peptide precursor B
gene, NPPA - natriuretic peptide precursor A gene, AGTRAP - angiotensin II receptor-
associated protein gene.
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Table 1
Characteristics of the GRAPHIC Study
Variable Fathers (n=511) Mothers (n=512) Sons (n=508) Daughters (n=489)
Age (years) 53.8 (4.3) 51.8 (4.4) 25.0 (5.1) 25.9 (5.4)
Body mass index (kg/m2) 27.8 (3.9) 27.1 (4.5) 24.9 (4.1) 24.6 (5.0)
Clinic SBP (mmHg) 137.8 (18.4) 128.5 (18.3) 127.7 (13.0) 113.8 (11.9)
Mean 24-hour SBP (mmHg) 124.3 (11.5) 117.0 (11.4) 120.8 (8.1) 112.8 (7.2)
Clinic DBP (mmHg) 86.0 (10.7) 80.8 (10.4) 75.9 (9.6) 73.6 (8.6)
Mean 24-hour DBP (mmHg) 77.7 (7.2) 71.7 (7.6) 69.2 (6.5) 67.9 (5.2)
Antihypertensive treatment (%) 77 (15.1) 53 (10.4) 3 (0.6) 1 (0.2)
Data are means and standard deviations or counts and percentages
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